Vaxcyte (PCVX) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 15, 2026, with virtual attendance available for shareholders.

• Shareholders are encouraged to review proxy materials online or request copies by June 1, 2026.

Voting matters and shareholder proposals

• Election of three Class III directors to serve until the 2029 annual meeting or until successors are qualified.

• Ratification of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026.

• Advisory vote on the compensation of named executive officers (say-on-pay).

• Proxies may vote on other business that may properly come before the meeting.

Board of directors and corporate governance

• Nominees for Class III director positions: Olivier Brandicourt, M.D., Halley Gilbert, J.D., and Grant E. Pickering, M.B.A.